---
title: Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma
  Treated with Personalized Therapy
date: '2024-12-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39728056/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241227170555&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Background/Objectives: Current guidelines recommend Cisplatin/Gemcitabine/Durvalumab
  as first-line treatment for inoperable or recurrent cholangiocarcinoma (CCA). Molecular
  tumor boards (MTB) have the expertise to support organ-specific tumor boards with
  evidence-based treatment recommendations for subsequent lines of treatment, based
  on genomic tumor data and scientific evidence. This study evaluates the adoption
  of an MTB at a comprehensive cancer center in Germany and whether ...'
disable_comments: true
---
Background/Objectives: Current guidelines recommend Cisplatin/Gemcitabine/Durvalumab as first-line treatment for inoperable or recurrent cholangiocarcinoma (CCA). Molecular tumor boards (MTB) have the expertise to support organ-specific tumor boards with evidence-based treatment recommendations for subsequent lines of treatment, based on genomic tumor data and scientific evidence. This study evaluates the adoption of an MTB at a comprehensive cancer center in Germany and whether ...